Home » Newsletters » BioWorld Science

BioWorld Science

June 27, 2000

View Archived Issues

Eotaxin found to regulate gastrointestinal allergic reactions

Noninvasive technique for delivering therapeutic genes to the brain

F-1322 dropped from development after reaching phase II

ZK-807834 effective at lower doses and with less bleeding risk compared to other FXa inhibitors

Aviron and NIH extend FluMist agreement

E-5531 partially reverses LPS-induced cardiodepression in rat ventricular myocytes

Genzyme General files BLA for approval to market Fabrazyme

Human Genome Sciences initiates clinical trials of BLyS one year after discovery

ENDO 2000: LMW melanocortin receptor agonists reported to reduce food intake and body weight

Promycin clinical studies put on hold

Certain hexarelin analogues induce penile erection in rats, European researchers report at ENDO 2000

Schering AG to commence phase I clinical study with Oncolym

Tanox to study anti-factor D MAb in cardiopulmonary bypass model

CPH-82 fares well in comparison with methotrexate and in combination with other DMARDs

Icos acquires additional rights to Abbott's LFA-1 compounds

EULAR 2000 news: positive clinical data presented for late-stage Merck coxib

FDA advisory committee recommends approval of Zelmac for treatment of IBS in women

Dual sst2/sst5 receptor agonist with potential in acromegaly

BMS synthesizes nonimmunosuppressive neurotrophic agents

New compounds described by Dong-A for male erectile dysfunction

Novartis and Schering pursue novel therapeutic approach to angiogenic disorders

Neurocrine Biosciences presents new CRF receptor antagonists

Potent and selective inhibitors of HIV-1 replication under evaluation at Janssen

BASF's new signal transduction inhibitors act on protein kinases

Japanese patent covers new Meiji Milk peptide for H. pylori-related conditions

Two series of compounds inhibiting ribonucleotide reductase patented by Kyowa Hakko

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...